AEMD Stock Price Drops 24% Following Disappointing Earnings Report
PorAinvest
viernes, 27 de junio de 2025, 6:51 pm ET1 min de lectura
AEMD--
The earnings report fell short of market expectations, with analysts projecting an earnings per share of -$1.09. The stock's price target range provided by Wall Street analysts was between USD 4.50 and USD 56.00, with an average target price of USD 30.25, suggesting an upside of 1,628.57% from the current price of USD 1.75 [2].
GuruFocus estimates an impressive 5,036.08% upside for AEMD based on its GF Value metric, which is calculated using historical trading multiples, past business growth, and future performance forecasts. The estimated GF Value for AEMD is USD 99.64 over the next year [3].
Investors are concerned about the company's future prospects, and the market's reaction to the earnings report will be closely monitored. Despite the disappointing results, the consensus recommendation from brokerage firms is currently "Outperform," indicating a favorable outlook among analysts [2].
References:
[1] https://www.marketscreener.com/quote/stock/AETHLON-MEDICAL-INC-22881435/news/Aethlon-Medical-Inc-Reports-Earnings-Results-for-the-Full-Year-Ended-March-31-2025-50356636/
[2] https://www.gurufocus.com/news/2948836/aethlon-medical-aemd-poised-to-report-earnings-with-consensus-expectations-aemd-stock-news
[3] https://www.gurufocus.com/news/2949288/aethlon-medical-aemd-reports-widerthanexpected-annual-loss
AEMD stock plummeted 24% after the company reported earnings that failed to meet market expectations. Investors are disappointed with the financial results, leading to uncertainty about the company's future prospects. Wall Street analysts forecast an average target price of $4.50, implying an upside of 131.96% from the current price. The estimated GF Value for Aethlon Medical Inc is $99.64, suggesting a 5036.08% upside.
Aethlon Medical Inc (AEMD) stock experienced a significant drop of 24% following the release of its earnings report for the full year ended March 31, 2025. The company reported a net loss of USD 13.39 million, up from USD 12.21 million a year ago. The basic loss per share from continuing operations was USD 8.58, compared to USD 38.87 a year ago [1].The earnings report fell short of market expectations, with analysts projecting an earnings per share of -$1.09. The stock's price target range provided by Wall Street analysts was between USD 4.50 and USD 56.00, with an average target price of USD 30.25, suggesting an upside of 1,628.57% from the current price of USD 1.75 [2].
GuruFocus estimates an impressive 5,036.08% upside for AEMD based on its GF Value metric, which is calculated using historical trading multiples, past business growth, and future performance forecasts. The estimated GF Value for AEMD is USD 99.64 over the next year [3].
Investors are concerned about the company's future prospects, and the market's reaction to the earnings report will be closely monitored. Despite the disappointing results, the consensus recommendation from brokerage firms is currently "Outperform," indicating a favorable outlook among analysts [2].
References:
[1] https://www.marketscreener.com/quote/stock/AETHLON-MEDICAL-INC-22881435/news/Aethlon-Medical-Inc-Reports-Earnings-Results-for-the-Full-Year-Ended-March-31-2025-50356636/
[2] https://www.gurufocus.com/news/2948836/aethlon-medical-aemd-poised-to-report-earnings-with-consensus-expectations-aemd-stock-news
[3] https://www.gurufocus.com/news/2949288/aethlon-medical-aemd-reports-widerthanexpected-annual-loss
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios